Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The inc...
Main Authors: | Lacouture, Mario E., Dréno, Brigitte, Ascierto, Paolo Antonio, Dummer, Reinhard, Basset-Seguin, Nicole, Fife, Kate, Ernst, Scott, Licitra, Lisa, Neves, Rogerio I., Peris, Ketty, Puig, Susana, Sokolof, Jonas, Sekulic, Aleksandar, Hauschild, Axel, Kunstfeld, Rainer |
---|---|
Format: | Online |
Language: | English |
Published: |
AlphaMed Press
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061532/ |
Similar Items
-
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
by: Dummer, Reinhard, et al.
Published: (2014) -
Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
by: Vogt, Annika, et al.
Published: (2004) -
Evaluation of the ‘Hedgehog’ signaling pathways in squamous and basal cell carcinomas of the eyelids and conjunctiva
by: CELEBI, ALI RIZA CENK, et al.
Published: (2016) -
Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma
by: Cucchi, Danilo, et al.
Published: (2012) -
Hedgehog signaling promotes basal progenitor expansion and the growth and folding of the neocortex
by: Wang, Lei, et al.
Published: (2016)